Information Provided By:
Fly News Breaks for October 5, 2015
BSX
Oct 5, 2015 | 07:12 EDT
RBC expects the FDA to approve Boston Scientific's Synergy bioabsorbable stent soon. The firm is upbeat on the outlook for Synergy and thinks it can enable the company's 2016 results to beat expectations. RBC keeps a $20 price target and Outperform rating on the shares.